Clinical drug safety

Precision safety insights for clinical studies using LiquiPath™

The challenge

Drug safety monitoring is a major bottleneck in drug development

Current approaches are too slow, fragmented, and lack the sensitivity for early detection of organ injury. As a result, safety signals are detected too late, delaying development, increasing costs, and putting patients at risk.

30% of drugs fail during clinical studies due to unresolved toxicity

1 in 3 FDA-approved drugs are later linked to safety or toxicity issues

Human body with internal organs, front view.png

Drug-induced adverse events prevent life-saving therapies from reaching patients

Our solution

Real-time organ health

LiquiPath redefines how we can monitor drug safety. For the first time, a single blood sample can provide real-time insight into treatment response across multiple organs, moving beyond today’s single-organ tests.

Unmatched insights

Our multi-tissue monitoring approach enables early detection of subclinical toxicity before irreversible damage occurs. By combining rapid turnaround times with precise, repeatable monitoring, we aim to identify safety signals earlier, helping the right patients stay on treatment for longer.

LiquiPath

Traditional approaches
Non-invasive, precision monitoring
Single sample multi-organ surveillance
Early detection
Cell-type specific insights
Integrated efficacy & safety
Patient stratification
Fast turnaround times

Join the revolution

Early access customers will have the opportunity to shape the capabilities of our organ health platform before general availability

Contact us to learn more about how we can improve your safety monitoring approach